Formulation and Evaluation of Fast Dissolving Tablets of Sumatriptan Succinate
Sri Prakash Mishra1*, Alok Pal Jain2
ABSTRACT
Sumatriptan succinate (SUM) is potent and selective a 5-HT1D (5-hydroxy tryptamine 1D) receptor agonist used in the treatment of migraine and cluster headache. Sumatriptan Succinate undergoes extensive first pass metabolism with an oral bioavailability of approximately 15%. Hence the main objective of the study was to formulate fast dissolving tablets of sumatriptan succinate to achieve a better dissolution rate and further improving the bioavailability of the drug. Fast dissolving tablets of SUM were prepared by direct compression methods and blend was evaluated for the pre-compression parameters such as bulk density, compressibility, angle of repose etc. The tablets were prepared by using croscarmellose sodium, crospovidone and sodium starch glycolate as superdisintegrants in different concentration along with microcrystalline cellulose. Total six formulations were prepared and evaluated for hardness, friability, weight variation, content uniformity, wetting time, water absorption ratio, disintegration time and invitro drug release. In-vitro dissolution studies are performed by using phosphate buffer pH 6.8 at 75 rpm by paddle method. Overall, the formulation F4containing of croscarmellose sodium was found to be promising and has shown a disintegration time 45 sec. The stability studies were performed for two months (accelerated studies) as per ICH guidelines. The optimized formulation (F4) showed no significant variations for the tablets parameters and it was stable for the specified time period. Thus the results showed enhanced dissolution, which leads to improved bioavailability, improved effectiveness and hence better patient compliance.
[Full Text Article]